Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06517212 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Study acronym: TRIM-EBC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Start date changed from estimate of Aug 19, 2024 to Nov 26, 2024
    • Eligibility criteria shortened, about 95 words
    • Secondary endpoints revised (3)
    • Study description shortened, about 10 words
    • Site details revised
    • Study title shortened, about 9 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating tumor DNA (ctDNA) and freedom from the development of metastatic disease.
Trial Details
NCT Number NCT06517212
Lead Sponsor Baylor Research Institute
Conditions
(from sponsor)		 Breast Cancer, Breast Neoplasms, Breast Cancers
Related terms Breast Neoplasms
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov